Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Novavax Has Limited Downside from Here

By Chris Lau, InvestorPlace Contributor

As countries potentially adopt a once yearly vaccination booster schedule for Covid-19, you can expect steady earnings for NVAX stock.

Rivian Stock Is Too Discounted to Ignore

By Chris Lau, InvestorPlace Contributor

Rivian is down sharply from its peak reached shortly after its IPO as the EV bubble deflates and investors wait for results.

Why Hope Prevails Despite SPY Stock Being in Serious Trouble

By Chris Lau, InvestorPlace Contributor

The steep selling in S&P 500 (or SPY stock) will not last, as investors adjust for inflation and higher rates in the near term.

Buy Cloudflare Stock as a Big Panic Dip Approaches

By Chris Lau, InvestorPlace Contributor

Markets are still nervous about Cloudflare’s valuations, and justifiably so as the CDN firm invests in its infrastructure.

7 Top Stocks for February Ready for V-Shaped Bounce

By Chris Lau, InvestorPlace Contributor

Get these oversold stocks with strong fundamental strength before momentum carries them on the way up and at new highs.

Load More